Bayer Change in Accounts Receivable 2010-2025 | BAYRY

Bayer annual/quarterly change in accounts receivable history and growth rate from 2010 to 2025. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
  • Bayer change in accounts receivable for the quarter ending March 31, 2025 was $-4.700B, a 9.99% decline year-over-year.
  • Bayer change in accounts receivable for the twelve months ending March 31, 2025 was $-10.398B, a 20.31% increase year-over-year.
  • Bayer annual change in accounts receivable for 2024 was $0.213B, a 71.41% decline from 2023.
  • Bayer annual change in accounts receivable for 2023 was $0.746B, a 163.11% increase from 2022.
  • Bayer annual change in accounts receivable for 2022 was $0.283B, a 492.71% decline from 2021.
Bayer Annual Change in Accounts Receivable
(Millions of US $)
2024 $213
2023 $746
2022 $283
2021 $-72
2020 $794
2019 $16
2018 $2,924
2017 $-20
2016 $-611
2015 $-1,178
2014 $-1,454
2013 $-998
2012 $-581
2011 $N/A
2010 $N/A
2009 $N/A
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $32.302B $50.438B
Bayer AG is a life science company with core competencies in the areas of health care and agriculture. With the company's focus completely on the Life Science businesses, a new organizational structure was introduced effective Jan 1, 2016. Bayer Group now comprise exclusively of the Life Science businesses. The company started reporting in three segments ' Pharmaceuticals, Consumer Health and Crop Science ' from the third quarter of 2019. Both Animal Health and Currenta were reported as discontinued operations in the quarter. The company acquired U.S. seed giant Monsanto in June, 2018. With the acquisition, Bayer now has the strongest portfolio of seed and crop protection products for a wide range of crops and indications, the best research and development platform and the leading digital farming business.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $693.355B 45.36
Johnson & Johnson (JNJ) United States $426.685B 17.72
AbbVie (ABBV) United States $371.684B 19.87
Novartis AG (NVS) Switzerland $267.327B 14.48
Roche Holding AG (RHHBY) Switzerland $259.428B 0.00
Novo Nordisk (NVO) Denmark $252.094B 15.26
Merck (MRK) United States $210.114B 11.01
Pfizer (PFE) United States $140.774B 7.30
Sanofi (SNY) France $121.499B 12.04
Innoviva (INVA) United States $1.288B 12.69